PubMed Health⌕ Search

Biomedical subjects

Stacy H Shoshan

Publications and source records attributed to Stacy H Shoshan.

4 recordsLinked to original sources

Antibodies as oncogenes: a hypothesis.

We would like to put forward the hypothesis that cancer patients may produce autoantibodies that promote uncontrolled cell growth and thereby function as oncogenes. Dying cells release proteins that stimulate the production of autoantibodies, an event also known to occur during the earliest stages of tumor growth. If some of these autoantibodies are directed against cell surface hormone receptors, they could oligomerize the receptors and inadvertently transmit growth signals. The abnormal signals could result in uncontrolled cell proliferation and, eventually, oncogenesis. Thus, some specific autoantibodies from among the large repertoires of autoantibodies present in the sera of cancer patients are, in reality, oncogenes. If such oncogenic autoantibodies are indeed present and can be identified, inhibition of their molecular action may be an effective therapeutic modality.

Autoantibodies↗

Proteomics in cancer vaccine development.

Proteomics is a new scientific field aimed at the large-scale characterization of the protein constituents of biologic systems. It facilitates comparisons between different protein preparations by searching for minute differences in their protein expression repertoires and the patterns of their post-translational modifications. These attributes make proteomics perfectly suited for searching for proteins and peptides expressed exclusively or preferentially in cancer cells as candidates for cancer vaccines. The main proteomics technologies include 2D polyacrylamide gel electrophoresis, multidimensional high-performance liquid chromatography, mass spectrometry and protein arrays. Proteomics technologies used to analyze cancer culture cells, fresh tumor specimens, human leukocyte antigen peptides, serum and serum antibodies (serologic proteomics) have successfully identified tumor markers. Turning the potential vaccine candidates identified by proteomics technologies into clinical treatments awaits demonstration.

Animals↗

MHC-bound antigens and proteomics for novel target discovery.

The MHC molecules present normal as well as disease-related and pathogen-derived peptides to T cells as a way of alerting the immune system of the health status of a cell. Proteomic technologies involving immunoaffinity purification are now extensively used to separate MHC complexes from their peptide cargo, and then the peptides are sequenced by tandem mass spectrometry. The identified peptides are tested as vaccine candidates for viral diseases, immunostimulants for treating cancer, and immune-tolerance-inducing agents for autoimmune disorders. One of the challenges in devising novel HLA-peptide-based immunotherapies is to decipher whether a therapeutic window exists between the induction of tumor immunity and the onset of autoimmunity, which can have dangerous sequelae. This review will cover these topics with an overview of the vast possibilities emerging in the field of proteomic analyses of MHC-bound antigens as novel targets for immunotherapy.

Animals↗